Details of the Drug

General Information of Drug (ID: DMLVQKF)

Drug Name
MRX-6
Synonyms
CXCL10 gene inhibitor/phospholipase A2/ MIP 1 ligand inhibitor (contact dermatitis), Morria Biopharmaceuticals; IL 1 beta/IL-6/PGE 2 modulator (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Monocyte chemotactic protein 1/GM-CSF/TNF alpha ligand inhibitor (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Non-steroidal multifunctional anti-inflammatory drug (MFAID) (topical formulation, contact dermatitis), Morria
Indication
Disease Entry ICD 11 Status REF
Contact dermatitis EK0Z Phase 2 [1]
Cross-matching ID
TTD ID
D07RKO

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phospholipase A2 (PLA2G1B) TT9V5JH PA21B_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Contact dermatitis
ICD Disease Classification EK0Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phospholipase A2 (PLA2G1B) DTT PLA2G1B 2.65E-01 -0.08 -0.21
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02031445) Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%. U.S. National Institutes of Health.
2 A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.